fig2

Figure 2. Ivosidenib increases the sensitivity of ovarian cancer cells to cisplatin. (A) Dose-response curves of SKOV3, CAOV3, and OVCAR4 detected by MTT assay treated with cisplatin and 0 μM, 1 μM, 5 μM, 10 μM, 20 μM, and 50 μM Ivosidenib for 72 h. Data represent mean ± SD of three biologically independent experiments. (B) The lC₅₀ of SKOV3, CAOV3, and OVCAR4 to cisplatin in (A) were calculated by Graph Pad Prism 9.5.0. Data represent mean ± SD of three biologically independent experiments. ns, not significant, ***P < 0.001; ****P < 0.0001 using a one-way ANOVA followed by Tukey's post hoc test for multiple comparisons. (C) Dose-response curves of SKOV3, CAOV3, and OVCAR4 were detected by the MTT assay and treated with Ivosidenib after 72 h. Data represent mean ± SD of three biologically independent experiments. (D) Fa-CI plot of combined treatments of cisplatin (0.5 μM, 5 μM, 10 μM, 20 μM, 50 μM, 100 μM) and Ivosidenib (5 μM, 10 μM) of SKOV3, CAOV3, and OVCAR4 cells. The combination index was calculated using CompuSyn software. CI < 1, =1, and >1 indicate synergistic, additive, and antagonistic effects, respectively. CI, Combination index. Fa, Fraction affected. Each score represents data from three biologically independent experiments. (E) CI scores of SKOV3, CAOV3, and OVCAR4 cells treated with Ivosidenib in combination with cisplatin at the indicated concentrations. Each CI score represents data from three biologically independent experiments.